Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionQuadrant Capital Group Llc
Latest Disclosed Ownership5,716 shares
Latest Disclosed Value $ 2,552,423
Quadrant Capital Group Llc reports 17.86% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Quadrant Capital Group Llc filed a 13F-HR/A form disclosing ownership of 5,716 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,552,423 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 4,850 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 17.86% during the quarter. The current value of the position is $2,524,986 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,716 866 17.86 2,552 16.11 0.0763
2026-05-11 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,716 866 49 0.0369
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,850 -825 -14.54 2,199 -1.08 0.0664
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,675 570 11.17 2,223 -2.20 0.0723
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,105 -233 -4.36 2,273 -12.18 0.0818
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,338 2,841 113.78 2,588 157.41 0.0961
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,497 12 0.48 1,006 -12.99 0.0692
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,485 4 0.16 1,156 -0.60 0.0803
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,481 135 5.75 1,163 18.57 0.0863
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,346 27 1.16 981 3.92 0.0774
2024-02-08 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,319 72 3.20 944 20.74 0.0810
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,247 -14 -0.62 781 -1.76 0.0782
2023-08-10 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,261 -80 -3.42 796 7.87 0.0789
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,341 336 16.76 738 27.29 0.0768
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,005 -7 -0.35 579 -0.69 0.0656
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,012 161 8.70 583 11.69 0.0771
2022-08-09 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,851 329 21.62 522 31.49 0.0701
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,522 100 7.03 397 27.24 0.0481
2022-02-01 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,422 230 19.30 312 44.44 0.0372
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,192 -148 -11.04 216 -20.00 0.0301
2021-08-09 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,340 -112 -7.71 270 -13.46 0.0392
2021-05-12 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,452 32 2.25 312 -7.14 0.0506
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,420 155 12.25 336 -2.33 0.0624
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,265 16 1.28 344 -5.23 0.0750
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,249 -1,263 -50.28 363 -38.89 0.0803
2020-05-15 2020-03-31 13F Vertex Pharmaceuticals Com 92532F100 2,512 406 19.28 594 36.55 0.0994
2020-03-19 2019-12-31 13F/A-1 Vertex Pharmaceuticals Com 92532F100 2,106 229 12.20 435 42.62 0.0525
2020-02-03 2019-12-31 13F Vertex Pharmaceuticals Com 92532F100 2,106 229 435 1,469.9218
2019-10-24 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,877 65 3.59 305 -4.39 0.0469
2019-07-24 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,812 266 17.21 319 18.15 0.0505
2019-04-29 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,546 693 81.24 270 116.00 0.0474
2019-01-17 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 853 169 24.71 125 2.46 0.0333
2018-10-29 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 684 31 4.75 122 23.23 0.0349
2018-08-08 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 653 -48 -6.85 99 -1.00 0.0347
2018-05-10 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 701 74 11.80 100 17.65 0.0363
2018-01-31 2017-12-31 13F Vertex Pharmaceuticals COM 92532F100 627 3 0.48 85 -2.30 0.0339
2017-10-13 2017-09-30 13F Vertex Pharmaceuticals COM 92532F100 624 37 6.30 87 26.09 0.0359
2017-08-14 2017-06-30 13F Vertex Pharmaceuticals COM 92532F100 587 65 12.45 69 35.29 0.0305
2017-04-10 2017-03-31 13F Vertex Pharmaceuticals COM 92532F100 522 64 13.97 51 75.86 0.0224
2017-01-11 2016-12-31 13F Vertex Pharmaceuticals COM 92532F100 458 -97 -17.48 29 -25.64 0.0145
2016-10-25 2016-09-30 13F Vertex Pharmaceuticals COM 92532F100 555 52 10.34 39 8.33 0.0254
2016-07-28 2016-06-30 13F Vertex Pharmaceuticals COM 92532F100 503 66 15.10 36 16.13 0.0248
2016-04-27 2016-03-31 13F Vertex Pharmaceuticals COM 92532F100 437 -518 -54.24 31 -73.28 0.0201
2016-01-28 2015-12-31 13F Vertex Pharmaceuticals COM 92532F100 955 -22 -2.25 116 17.17 0.0803
2015-10-28 2015-09-30 13F Vertex Pharmaceuticals COM 92532F100 977 85 9.53 99 -9.17 0.0683
2015-08-12 2015-06-30 13F Vertex Pharmaceuticals COM 92532F100 892 892 109 0.0694
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.